AACR 2024 | Employing fragmentomics as a novel strategy to characterize and detect cancers

Alain Thierry, PhD, INSERM U896 – IRCM, Montpellier, France, summarizes advances in fragmentomics, a novel strategy examining the fragmentation patterns of cell-free circulating DNA (cirDNA) for cancer screening purposes. Using low-pass whole genome sequencing, fragmentomics affords the capacity to detect and profile fragment size patterns, which can be utilized to reliably differentiate individuals with cancer and healthy individuals. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.